RMS Medical Announces Hiring of Eric Bauer as Chief Operating Officer
Premier provider of Medical Device Systems and Supplies Strengthens Executive Team
CHESTER, NY / ACCESSWIRE / January 20, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) ("RMS" or the "Company") announced today that Mr. Eric Bauer has joined the executive team as Chief Operating Officer, effective January 17, 2017. Mr. Bauer brings to RMS over 25 years of experience driving operational excellence in growing organizations within FDA regulated environments.
Prior to joining RMS Medical Products, Mr. Bauer was Chief Executive Officer of 2020Value, LLC, a consulting business leveraging his extensive operating experience to help clients maximize long-term sustainable value. From 2011 to 2015, Mr. Bauer served as Founder and Chief Executive Officer of KAKO Beauty Products, a cause-oriented provider of skin care goods benefiting the Medical Research Center for Childhood Cancer. From 2008 to 2011, Mr. Bauer was the Chief Executive Officer of Chemaid Laboratories, a Private Equity-owned contract manufacturing company providing high quality skin care, haircare, fragrance, and bath products to the prestige cosmetics industry. At Chemaid, Mr. Bauer emphasized a culture focused on operational excellence, product quality, and customer service, resulting in a doubling of revenue, 400% increase in EBITDA, and significantly increasing shareholder value during his tenure. From 2002 to 2008, Mr. Bauer served as President of Valois of America, Inc., an international consumer packaged goods manufacturing company providing high quality pumps to the Luxury Fragrance/Cosmetic and Pharmaceutical Industries in North America. As President, Mr. Bauer oversaw operations with FDA regulated Class 10,000 clean rooms and had responsibility for all manufacturing, sales, and service. During his six year tenure with Valois, Mr. Bauer spearheaded $80 million in sales growth from $40M to $120M and increased productivity by 200%. Mr. Bauer began his career with Eastman Kodak where he served in various managerial positions over his 22 years tenure with the company. Mr. Bauer earned his MBA in Finance and Economics at the University of Rochester and his BS in Industrial Engineering at the State University of Buffalo. Mr. Bauer also attended Executive Development Programs at Duke University, MIT, and Columbia University.
Andrew Sealfon, CEO of RMS, stated, "Bringing Eric on board reaffirms our commitment to a robust growth strategy coupled with delivering long-term value to our shareholders. With Eric's experience in successfully building and managing businesses from the tens to hundreds of millions of revenue, he will be instrumental in helping us achieve accelerating organic revenue growth, while maintaining our strong brand reputation in the market and streamlining operations to ensure efficient execution as we grow. We are delighted Eric has joined the RMS team and look forward to his dynamic contributions with a promise of bright future."
Mr. Bauer commented, "I'm thrilled to be a part of the RMS team. It is an honor to be part of such a highly respected organization dedicated to improving the quality of life of so many patients around the world. With an exciting new product pipeline and expansion of global sales, the future of RMS is very bright."
About RMS Medical Products
The Company manufactures medical products used for infusions and suctioning. The Infusion product portfolio currently includes the FREEDOM60® and our latest FreedomEdge® Syringe Infusion Pumps, RMS Precision Flow Rate Tubing™, and RMS HIgH-Flo™ Subcutaneous Safety Needle Sets. These devices are used for infusions administered in professional healthcare settings, as well as at home. The Company's RES-Q-VAC® line of medical suctioning products is used by emergency medical service providers, in addition to a variety of other healthcare providers.
The Company's website may be visited at www.rmsmedicalproducts.com.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.
For more information, please call:
702 650 3000
SOURCE: Repro Med Systems, Inc.
Released January 20, 2017